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Two dosing schedules of intravenous tissue plasmin- 
ogen activator (t-PA) for acute myocardial infarc- 
tion were compared in a multicenter trial. At 2.95 f 
1.1 hours from onset of chest pain, 388 patients re- 
ceived 150 mg of intravenous t-PA. For the first 
178 patients (group A), 80 mg were given in the 
first-hour dose and the remaining 90 mg were in- 
fused over 7 hours. In the subsequent 208 patients 
(group B), the first-hour dose was 1.0 mg/kg and 
the remaining 150 mg were given over 5 hours. At 
initial angiography 94 f 30 minutes into therapy, 
the infarct vessel patency was 84% in group A ver- 
sus 75% in group B (p = 0.02). By final angiogra- 
phy with up to 4 selective contrast injections, paten- 
cy was 88 % versus 77 % , respectively (p = 0.08). 
Repeat angiography at 7 to IO days demonstrated 
reocclusion in 17 % of group A and 13 % of group B 
patients (p = 0.35). There was no difference in fi- 
brinogen nadir or mean hematocrit drop between 
the 2 groups: 120 mg/dl and 11 points, respective- 
ly, in group A compared with 120 mg/dl and 10 
points in group B. However, bleeding was reduced 
in group B patients as evident by a decrease in re- 
quirement for 22 units of packed red blood cell 
transfusion (group A 38 % , group B 27 % , p = 
0.05) and lower incidence of gastrointestinal bleed- 
ing (group A 12%, group B 4%, p = 0.002). To 
further study the importance of weight adjustment, 
patients were divided into 2 groups according to 
weight (<go kg versus >gO kg). According to the 
results, lighter weight patients had greater transfu- 
sion requirements (35% versus 20%, p = 0.008) 
and more frequent major bleeding episodes (18% 
versus 7 % , p = 0.025). Thus, a higher, weight-ad- 
justed first-hour dose of intravenous t-PA, with a 
shorter duration of maintenance infusion, is associ- 
ated with: (1) improved infarct vessel patency; (2) 
more rapid recanalization; and (3) less bleeding 
complications without more fibrinogenolysis. 
(Am J Cardiol 1988;81:723-728) 
s ince the clinical introduction of recombinant tis- 
sue-type plasminogen activator (t-PA) for myocardial 
infarction in 1984, there has been considerable growth 
in our understanding of its pharmacology and a signifi- 
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cant change in production methods. Although very low 
doses of intravenous t-PA were initially used for a 
brief duration (1 to 3 hours),l-4 more recent trials have 
employed a larger first-hour dose and a prolonged 
maintenance infusion.5r6 The initial studies used a pre- 
dominant z-chain form of t-PA which was not suitable 
for iarge-scale production. The single-chain form oft- 
PA subsequently introduced has a clearance 40% 
more rapid than the original preparation and thereby 
has required a new pharmacologic evaluation for opti- 
mal dosing.5 Although high doses of this form of intra- 
venous t-PA were demonstrated to promote rapid re- 
canalization7 they were associated with an increased 
rate of serious hemorrhagic episodes which led to a 
recommendation for a decreased dose.8rg Thus, contro- 
versy exists as to the optimal dosing of this fibrinolytic 
enzyme for achieving maximal coronary thrombolytic 
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TABLE I Comparison of the Two Dose Regimens 
Group A Group B 
(n = 178) (n = 208) 
Total dose (ma) . -. 





80 mg 1 .O mg/kg 
90 150 - first-hour dose 
7 5 
TABLE II Baseline Characteristics* 
Group A Group B 









Time CP - t-PA (hrs) 





Systolic blood pressure (mm Hg) 
Heart rate (beatslmin) 
58f 10 58f 11 
81 78 










134 f 25 138 f 28 
82f 18 79f 19 
+ There were no significant differences (p <0.05) between groups for the 
variables listed. 
t Although 208 patients were treated with this dosing regimen, 2 did not 
undergo acute catheterization. 
t Number of major epicardial vessels with 250% stenosis. 
CP = chest pain: LAD = left anterior descending; LC = left circumflex. 
efficacy with the least possible rate of bleeding com- 
plications. The present study was undertaken to deter- 
mine which of 2 t-PA dosing regimens employed in a 
multicenter trial was superior in terms of frequency 
and speed of coronary artery recanalization, effects on 
hemostasis and the coagulation system, and the impor- 
tance of weight adjustment. 
Methods 
The Thrombolysis and Angioplasty in Myocardial 
Infarction (TAMI] study design has been previously 
described in detaillo To summarize, selection criteria 
were: (1) patients with 14 hours of chest discomfort or 
severe symptoms with a duration of 4 to 6 hours, and 
ongoing pain; and (2) at least 1 mm of electrocardio- 
graphic ST-segment elevation in 2 contiguous leads. 
Patients were excluded for age >75, recent (<6 
months] trauma, surgery or stroke, prolonged cardio- 
pulmonary resuscitation, prior coronary artery bypass 
grafting, cardiogenic shock and previous transmural 
infarction in the same area. All patients provided in- 
formed consent and the protocol was approved by the 
institutional review board at the respective clinical 
site. 
In the trial, the predominantly single-chain form of 
t-PA was used.5 The first 178 patients received an in- 
travenous t-PA dose based on schedule A: 60 mg in the 
first hour given as a 6-mg bolus and 54-mg drip, and 
then 20 mg for each of 2 hours, followed by 10 mg/hr 
for 5 hours with a total dose of 150 mg. In the subse- 
quent 208 patients (schedule B], the same total dose of 
150 mg was administered using weight adjustment and 
a briefer maintenance infusion as follows: 1 mg/kg for 
the first hour with 10% as a bolus and a maximum dose 
of 90 mg, and the remainder of 150 mg over the next 5 
hours. The patient’s report provided the information 
on body weight required for dosing. The dose regi- 
mens are summarized in Table I. 
After initiation of t-PA, the patients were trans- 
ferred to the cardiac catheterization laboratory of the 
respective clinical site for acute angiography. Nonion- 
ic contrast dye was used. The first contrast injection of 
the infarct vessel was performed after 60 minutes of 
therapy and images obtained no later than 90 minutes. 
An exception to the latter occurred when difficulties 
arose in obtaining arterial access or interhospital 
transport was delayed. The final determination of in- 
farct vessel patency was made at 90 minutes, after up 
to 4 injections of the infarct-related artery. 
The perfusion status was classified according to the 
TIM1 (Thrombolysis in Myocardial Infarction Study 
Group) grading systemn2 For the purpose of this study, 
TIM1 0 and 1 were considered occluded and TIM1 2 or 
3 patent. The angiograms were subsequently reviewed 
at the core angiographic laboratory for verification of 
the final TIM1 grade determination. 
On the basis of the go-minute infarct vessel angio- 
gram, patients were triaged to 3 different groups as 
follows: (1) persistent occlusion-coronary angioplasty 
was considered at the discretion of the investigator; (2) 
patent, 150% residual stenosis, suitable for angio- 
plasty-patients were randomized to undergo the pro- 
cedure immediately or at 7 days; (3) patent, with coro- 
nary anatomy unsuitable for angioplasty. Emergency 
coronary artery bypass surgery was defined as a direct 
transfer from the cardiac catheterization laboratory 
during the acute study to the operating room. The pro- 
cedure was performed for failed percutaneous trans- 
luminal coronary angioplasty or high-risk coronary 
anatomy. In the first 50 patients from the aforemen- 
tioned groups 1 and 3, only the first 3 hours of t-PA (100 
mg] were infused (all in group A patients). Angioplas- 
ty’s complete success was defined as X50% residual 
stenosis and partial success as 150% residual stenosis 
after balloon dilatation. 
Concomitant medical therapy consisted of heparin 
(5,000 U at access, 5,000 U at the time of angioplasty if 
performed acutely, and 500 to 1,000 U/hr for L3 days 
by continuous infusion adjusted to 2.5 to 3 times the 
partial thromboplastin time], aspirin (325 mg/day], di- 
pyridamole (75 mg, 3 times daily] and diltiazem (30 to 
60 mg, 4 times daily]. 
At 7 to 10 days, patients underwent repeat cardiac 
catheterization to determine infarct vessel patency 
and left ventriculography. Besides the paired studies, 
patients returned to the catheterization laboratory be- 
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fore 7 days had elapsed if recurrent ischemia oc- 
curred, as defined by 120 minutes of chest discomfort 
associated with electrocardiographic changes. After 
urgent angiography in these patients, who by now had 
reached a clinical endpoint, either coronary angio- 
plasty or bypass surgery was performed and followed 
by a repeat (third] cardiac catheterization, whenever 
possible, before hospital discharge. Reocclusion was 
defined by angiographic documentation of flow pat- 
tern as TIM1 grade 0 or 1 and flow pattern diagnosed 
subsequent to established perfusion as TIM1 2 or 3.2 
Bleeding complications were characterized accord- 
ing to: (1) site; (2) need for transfusion of 12 units of 
packed red blood cells for augmentation of hematocrit 
>3O; and (3) baseline and nadir hematocrit values. 
Gastrointestinal bleeding referred to either guaiac- 
positive results or frank blood in emesis or stool. Intra- 
cranial and retroperitoneal hemorrhage was diag- 
nosed using computed axial tomographic scanning. 
Assessment of coagulation proteins included assay of 
the serum fibrinogen by the Clauss and sodium sulfite 
precipitation methods11J2 and the fibrinogen degrada- 
tion product titer I3 by tanned red cell agglutination 
method at baseline, 3, 8 and 12 hours afl:er t-PA. 
Statistical analysis: Values are expressed as mean 
f 1 standard deviation unless otherwise specified. 
Comparison of group A versus group B patients was 
made using chi-square analysis for dichotomous vari- 
ables and an unpaired t test or Wilcoxon log-rank test, 
as specified, for continuous variables. The comparison 
between the 2 dose regimens was performed with and 
without those 50 patients in group A who received 100 
mg instead of 150 mg of t-PA. For analysis of the impor- 
tance of weight (190 or >90 kg], chi-square analysis 
was used for dichotomous variables, a Wilcoxon rank- 
sum test for continuous variables and a logistic regres- 
sion model for testing the relation between the 2 
weight groups for multiple variables. 
Results 
Study population: The relevant demographic char- 
acteristics for the 2 patient groups are summarized in 
Table II. Patients receiving the 2 different dose regi- 
mens were similar with regard to the baseline hemo- 
dynamic, angiographic and demographic features. 
Patency of the infarct vessel: Table III lists the 
results for acute and follow-up (before discharge) in- 
farct vessel perfusion status. A significantly higher pa- 
tency was demonstrated for group B patients at the 
initial angiogram. As demonstrated in Figure 1, nearly 
all patients in group B who demonstrated infarct vessel 
recanalization were already patent at the initial angio- 
gram. The residual stenosis of the infarct vessel was 
significantly decreased in group B patients compared 
with group A (Figure 2). The results for initial angio- 
graphic patency excluding the 50 patients in group A 
who did not receive the full 150 mg t-PA dose were: 
group A, 68% patent; group B, 75% patent; p = 0.16. 
Acute coronary angioplasty was performed in 89 
patients in group A and 93 patients in group B with 
complete or partial success in 73% versus 83%) respec- 
tively (p = 0.09). Emergency bypass surgery was neces- 
sary in 8% of group A patients compared to 4% in 
group B (p = 0.09). During hospitalization, a total of 39 
(22%] bypass surgery procedures were performed in 
group A compared with 44 (21%) in group B (p = 0.19). 
Intraaortic balloon counterpulsation was used in 11% 
of group A versus 6% of group B patients (p = 0.09). 
Bleeding complications and coagulation system 
effects: The transfusion requirement, admission and 
nadir hematocrits, and incidence of bleeding by site 
appear in Table IV. As shown, the frequency of gastro- 
intestinal bleeding was significantly higher in group A 
patients. Only 2 patients (both in group B) developed 
intracranial hemorrhage. Both patients were female 
with a history of longstanding hypertension, age 68 and 
73, respectively. 
In Figure 3, the serum fibrinogen values are plotted 
for the 2 dosage regimens. There was no difference in 
the nadir fibrinogen level (120 mg/dl for both groups). 
The median peak FDP titer was 1:16 in group A versus 
1:32 for group B. 
Influence of body weight: Patients were divided 
into 2 groups as shown in Table V. The baseline weight 
was not recorded in 5 patients enrolled in the trial. As 
expected, there was a significantly lower proportion of 
males in the 190-kg weight column. There were no 
differences (p <0.05] in patency of the infarct vessel, 
infarct location, presence of multivessel disease, group 
A or B dosing or bypass surgery. Lighter weight pa- 
tients underwent acute coronary angioplasty less fre- 
H INFARCT VESSEL STATUS AT FIRST INJECTION 
B OCCLUDED PATENT FINAL INFARCT VESSEL STATUS 
FIGURE 1. A, patency of the infarct vessel on first contrast injection. 
Group B patients demonstrated a significantly higher patency rate. 
B, patency of the infarct vessel after up to 4 injections at 90 minutes 
of tissue plasminogen activator (t-PA) therapy. A trend of higher 
patency was observed for group B patients. 
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TABLE Ill Patency of the infarct Vessel 
Group A Group B 
(n = 178) (n = 206) p Value 
Initial angiogram 
Time (min) 94f31 95f31 0.61 
TIM1 2 or 3 110/173 (64%) 1531205 (75%) 0.02 
Final angiogram’ 
TIMI 2 or 3 119/167 (66%) 157/205 (77%) 0.06 
Recurrent ischemic events 50 (28%) 58 (27%) 0.78 
Reocclusion on follow-up 30 (17%) 28 (13%) 0.24 
angiogram (1 week) 
* Final angiogram after up to 4 injections of the infarct vessel at the 90- 
minute point of t-PA therapy. 
TIMI 2 or 3 = Thrombolysis in Myocardial Infarction Study Group’s grade 2 
or 3 (perfusion status patent). 
quently (45 versus 58%, respectively, p = 0.0231 and 
had a higher success rate for angioplasty (84 versus 
68%, p = 0.06). 
Despite less invasive procedures performed in the 
lighter weight patient group (equivalent to a 21% by- 
pass surgery rate during hospitalization, less acute an- 
gioplasty], their transfusion requirement was higher, 
with major bleeding episodes more frequent as con- 
firmed by a significantly lower nadir hematocrit (Ta- 
ble V]. In addition, these patients had a lower nadir 
plasma fibrinogen and a decreased likelihood of reoc- 
elusion. 
Discussion 
In the current study, 2 different t-PA dose regimens 
with the same 150 mg cumulative dose were com- 
pared. The second regimen, which provided for a 
weight-adjusted first-hour dose and a lesser duration 
of maintenance infusion, was found to be superior 
with respect to frequency and rapidity of infarct vessel 
patency, decreased transfusion requirement and over- 
all bleeding complications, without more extensive 
fibrinogenopenia. 
Comparison with previous studies: There have 
been 3 previous trials using the single-chain prepara- 
tion of t-PA. In the randomized trial of Top01 et al5 
0.75 mg/kg of t-PA was given over the first hour and 
0.25 mg/kg per hour over the subsequent 2 hours. In- 
farct vessel patency at 90 minutes was 69% and in- 
creased to 79% at 120 minutes. Using criteria for 
bleeding complications similar to those adopted in the 
current study, 29% received transfusion, gastrointesti- 
nal bleeding occurred in l.l%, genitourinary bleeding 
in 5% and the fibrinogen nadir was 62% of baseline. 
Reocclusion was not systematically determined but 
the angiographically confirmed incidence was 20%. 
As recently reported by Mueller et a1,7 the open-label 
Thrombolysis in Myocardial Infarction (TIMI) multi- 
center trial was divided into 5 separate groups [A 
through E). In the E phase, 167 patients received a dose 
of 90 mg over the first hour and 60 mg over the subse- 
quent 4 hours. A high rate of infarct vessel patency 
resulted (85% at 120 min), albeit accompanied by a 
1.6% incidence of intracranial hemorrhage. This re- 
sulted in a recommendation for a lower dose: 60 mg in 
the first hour and a cumulative dose of 100 rngn8 
The dose of 150 mg used in the TAM1 trial achieved 
a high proportion of infarct vessel patency without 
inducing an unacceptable rate of serious bleeding epi- 
sodes Although the overall transfusion rate and peri- 
access bleeding incidence was somewhat higher com- 
pared to other trials, all TAM1 patients underwent 
emergent angiography per protocol, with a significant 
proportion (21%) undergoing coronary artery bypass 
surgery. Nearly all of these patients received transfu- 
sion 
First-hour dose: The dose of t-PA in the first hour 
appears to be a critical determinant of the time of 
recanalization. As previously demonstrated by TIM1 
with baseline angiography, increasing the dose from 
50 to 90 mg did not yield significantly higher patency at 
90 minutes of therapy, but the speed of achieving re- 
perfusion was markedly enhanced.7 In the current tri- 
al, the higher first-hour dose used in group B was asso- 
ciated with more rapid recanalization and a trend 
01 
% STENOSIS OF INFARCT RELATED ARTERY 
FIGURE 2. Infarct-related artery percent dlameter stenosis for 
group A versus group B patients at the final angiogram obtained 
during the acute study. A comparison of group A with group B 
patients shows an overall higher grade residual stenosis for group 
A. 
TIME AFTER t-PA INITIATION (hrs) 
FIGURE 3. Plasma fibrinogen levels (sulfite precipitation method)12 
versus time after tissue plasminogen activator (t-PA) therapy. 
There were no significant differences between the 2 dose groups for 
nadir fibrinogen values. 
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toward a higher proportion of infarct vessel patency at 
the final angiogram. 
Weight adjustment: The results of this study fur- 
ther confirm the importance of a weight-adjusted dose 
of t-PA. In previous studies by Tap01 et all4 and Gold 
and co-workers,6J5 the utility of a weight-adjusted 
dose and its increased safety have been demonstrated. 
Even though a higher dose was employed in TAMI’s 
group B patients, an overall decreased bleeding com- 
plication rate resulted which likely reflects weight ad- 
justment. Patients weighing <90 kg had a definite in- 
creased risk of bleeding complications compared with 
heavier patients. In contrast, with a higher weight- 
adjusted first-hour dose of t-PA, there was an increase 
in rate and proportion of infarct vessel patency. Thus, 
in order to avoid bleeding episodes and a high transfu- 
sion requirement, patients weighing <60 kg should 
probably receive a lower than 60 mg first-hour dose of 
t-PA. Group B data suggest that patients weighing up to 
90 kg derive benefit from the higher dose in terms of 
coronary recanalization. Because doses >90 mg were 
not given in the first hour, the relative effects of throm. 
bolysis versus hemorrhage remain speculative in pa- 
tients >90 kg. 
Maintenance infusion: As demonstrated by Gold et 
a1,6 the purpose of the maintenance infusion is to in- 
crease the extent of coronary thrombolysis and limit 
rethrombosis. The ideal length and dose requirement 
of such a prolonged infusion have not yet been deter- 
mined. In 1 recept study, too long an infusion has been 
reported to yield a high rate of periaccess bleeding that 
may be unacceptable? whereas in a receqt multi- 
center trial with a predominant Z-chain form of t*PA, 
up to a %hr low-dose infusion has been tested with 
apparent low reocclusion and bleeding rate compliqa- 
tion.17 
In the current trial, a possible explanation for the 
increased bleeding observed in patients from group A 
is the lack of weight adjustment and the duration of 
maintenance infusion for 7 rather than 5 hours [group 
B). The additional 2 hours of maintenance infusion 
may be significant, as reflected by the 3-fold increase 
in gastrointestinal bleeding in group A, most of which 
was initially manifest during the infusion. The in- 
creased bleeding with longer maintenance infusions 
may reflect sustained fibrinolytic action of t-PA, Al- 
though the half-life of this trPA preparation is <3 mia- 
utes,5 the beta phase half-life is more than 20 minutes18 
and this ongoing fibrinolysis proceeds despite physio? 
logic plasma levels of t-PA.lg It would therefore be 
anticipated that in group A patients there was a coqsid- 
erably longer pharmaoologic fibrinolytic effect. Be- 
cause reocclusion was actually not increased in group 
B patients, our data suggest that a shorter maintenance 
infusion of 5 hours may be preferable to 7 hours in 
achieving the purpose of limiting rethroqbosis with- 
out promoting bleeding. 
Effects of dose on angioplasty success rate: A trend 
toward a higher success rate in acute coronary angio- 
plasty was observed among group B patients, along 
with a decrease in the need for emergency bypass 
surgery. Althovgh this observation may theoretically 
TA&E IV Bleeding Complications 
Group A Group 6 
(n = 178) (n = 208) 
Transfusion 
)2 U PRBC 
Admission hematocrit (%) 




l p=o.o5:, -’ 
+ p = 0.002. 
64 (36%) 56 (27%)’ 
43 f 6 44 f 4 
ii f6 32 f 5 
21 (12’%) 8 (4%)+ 
0 (0%) 2 (0.9%) 
1 (0.6%) 1 (0.5%) 
U PRBC = units pf packed req blood cells. 
TABLE V Effect of Body Weight on Bleeding, Coagulation 
Factors and Rethrombosts 
No. 
Men’ 
Transfused 22 U PRBC 
Major bleeding+ 
Reocclusion 
Nadir Hct (median) 


























* Regression analysis has shown that lighter weight, independent of female 
sex, was associated with increased bleeding risk.” 
t Major bleeding refers to observed blood lass >I50 ml. 
t Continuous variables were analyzed using the Wilcoxon rank-surp test. 
Hct = hematocrit; U PRBC = units of packed red blood cells. 
be attributed to enhanced coronary thrombolysis (with 
facilitation of the dilatation procedure], it also may be 
related to a learning curve phenomenon during the 
TAM1 trial. This point brings up the chief limitation of 
the current study: although a relatively large sample 
size at each of the 2 dose schedules was studied, this 
was a consecutive series and not a randomized com- 
parison. Selection of patients for randomization to an- 
gioplasty was determined by the investigators. Duriqg 
the course of the trial, a trend toward decreased ran- 
domization to angioplasty and less need for emergency 
bypass surgery was noted, so that it remains unclear 
whether the dose change actually served as a pivotal 
factor for angioplasty: success.zo 
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